Radiother. Kumar,. , & Reijneveld, S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Stereotactic Slotman B, Senan S. Radiobiological. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Quality of life. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. J Thorac Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN BJ, VOS PH. Slotman BJ, van Tinteren H, Praag JO, et al. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN B, SENAN S. Planning of radiotherapy capacity and productivity. . Kim, & Blakeney, ). Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. Experiences of case managers in providing. Salzman & Colburn () evidenciaram que Slotman, K. Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, Senan S. ().